Smarter Team

About the Author Smarter Team

Smarter Analyst was established to fill a gap in financial reporting for sell-side investors, where they can read exclusive reports in real time. Smarter Analyst provides coverage of equities research, unique analyst insights, and outstanding articles from knowledgeable contributors, in addition to the latest stock market news, all hand-picked by our editors.

MannKind Has Much Room for Upside in Diabetes Market: Here’s Why

MannKind Corporation (NASDAQ:MNKD) could be ready to capture an enticing amount of diabetes market share despite what the Street mostly dismissed as a …

H.C. Wainwright Upbeat on OncoSec Medical Following Updated Phase 2 Data

OncoSec Medical (NASDAQ:ONCS) just hit clinical trial results out of the park in the melanoma arena, with a Phase 2 combination trial that …

Otonomy Gets Another Vote of Confidence from SunTrust

Otonomy Inc (NASDAQ:OTIC) magnetized Street-wide attention after Wednesday’s triumphant Phase III home run in Meniere’s, leading investors to send the stock racing up 83% …

Valeant on the Mend? H.C. Wainwright Remains on the Sidelines Until Pipeline Strength Proves Itself a Gains Maker

Valeant Pharmaceuticals (NYSE:VRX) is in the middle of making a comeback, as investors breathed a sigh of relief thanks to a largely successful …

Here’s What Oppenheimer Has to Say About Roku

Roku Inc (NASDAQ:ROKU) is fresh out of the public company gates with a knockout third quarter that even has sidelined Oppenheimer analyst Jason Helfstein highlighting …

Valeant Pharmaceuticals Management Is Doing Commendable Job But Key Challenges Remain, Says BTIG

Valeant Pharmaceuticals (NYSE:VRX) is on the road to redemption after a robust third quarter earnings showcase has seen the company gain around 10% …

Keryx Biopharmaceuticals: This Analyst Blames Slowing Script Growth for Bad Q3 Outcome

Keryx Biopharmaceuticals (NASDAQ:KERX) has commercial adoption challenges ahead for its iron deficiency anemia asset Auryxia, says Cowen analyst Boris Peaker. After the company’s …

Does MannKind Have Enough Funds to Support the Afrezza Launch? 3Q Earnings Disaster Leaves Questions

It was a bad day to be a MannKind Corporation (NASDAQ:MNKD) investor yesterday after the biotech stock took an around 8% beating in the …

Opko Health Investors Got Spooked Today, But Analyst Louise Chen Bets on Long-Term Sales Potential

Opko Health Inc. (NASDAQ:OPK) delivered a sore sight to the Street yesterday with a sharp third quarter miss in earnings that has sent …

Seanergy Maritime Has Room To Run, Says Maxim In Hiking Price Target

Maxim analyst James Jang expressed his bullish opinion on Seanergy Maritime (NASDAQ:SHIP) after the company delivered a solid Q3 beat on the back …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts